Description: The 2023 Professionalism in Practice Course will study, discuss and explore the professionalism practice, code of conduct and application of the actuarial profession. Our speakers are seasoned presenters from mainland China. Experts will cover several issues encountered in daily actuarial working environments. Content will include business cases and interactive discussions, which aim to enrich the practical learning experience of attendees. Audience attendance will be limited in order to provide an interactive, collaborative learning experience. Early registration is highly recommended to secure a seat.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.